News | April 09, 2010

Trial Explores Smaller Stent Grafts for Abdominal Aortic Aneurisms

April 9, 2010 – The first patients have been enrolled in the INNOVATION trial, which will assess the safety of a new stent graft system to treat abdominal aortic aneurisms (AAA).

Current AAA stent-grafts limit the range of patients suitable for endovascular aneurism repair (EVAR). Delivery and accurate placement can also be challenging. The new Incraft stent graft is supposed to be easier to implant due to its smaller size. Currently available EVAR devices have a system profile ranging from 18 to 24 French. Incraft’s delivery system profile is 13 French.

The INNOVATION trial (multicenter, open-label, prospective, non-randomized study of the Cordis AAA stent graft system in subjects with abdominal aortic aneurysm) will enroll up to 25 patients at three sites throughout Germany.

“The ability to customize the Incraft system during the procedure is a very helpful feature for clinicians,” said professor Giovanni Torsello, chief of vascular surgery at St. Franziskus Hospital in Muenster.

The initial procedures using the device were performed by professor Dierk Scheinert, head of the department of medicine, angiology and cardiology at Park-Krankenhaus Hospital in Leipzig, who is serving as principal investigator of the INNOVATION trial. “We have been excluding a significant portion of our AAA patients, especially women, from EVAR because current stent grafts have large and bulky delivery systems, making device introduction impossible for small or diseased access vessels,” he said. “The ultra-low profile delivery system of Incraft will make EVAR a possible treatment alternative for a wider range of patients.”

“I believe the Incraft stent graft system has the potential to impact how we treat AAA patients globally.” said Takao Ohki, M.D., chairman of the department of surgery at Jikei University School of Medicine in Tokyo, who has one of the largest AAA practices in the world.

The trial is sponsored by Cordis and both investigators and sites are under contract with Cordis to perform this research. The Physician Advisory Panel members are compensated for their time by Cordis.
An estimated 27 million people worldwide have abdominal aortic aneurysms. Left untreated, all aneurysms will eventually rupture, and more than 80 percent of aneurisms that rupture result in death. In the U.S. alone, about 15,000 people die every year due to an AAA rupture.

For more information: www.cordis.com

Related Content

FDA Grants Breakthrough Device Designation for Valiant Thoracoabdominal Aortic Aneurysm Stent Graft
News | Stent Grafts | October 09, 2019
Medtronic plc announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA...
PQ Bypass Granted IDE Approval to Start TORUS SFA Stent Graft Pivotal Study
News | Stent Grafts | October 08, 2019
PQ Bypass Inc. announced it has received full approval of its investigational device exemption (IDE) trial of the...
First U.S. Patient Receives Gore Tag Conformable Thoracic Stent Graft With Active Control
News | Stent Grafts | July 10, 2019
W. L. Gore & Associates Inc. (Gore) announced the first U.S. implant of the Gore Tag Conformable Thoracic Stent...
Gore Receives FDA Approval for Gore Tag Conformable Thoracic Stent Graft
Technology | Stent Grafts | May 15, 2019
W. L. Gore & Associates Inc. (Gore) announced the U.S. Food and Drug Administration (FDA) has granted regulatory...
Aortic Stent Graft Global Market to Reach $5.4 Billion by 2028
News | Stent Grafts | February 14, 2019
Abdominal aortic stent grafts will remain the largest segment in the global aortic stent graft market at least through...
Medtronic Receives FDA Approval for Valiant Navion Thoracic Stent Graft System
Technology | Stent Grafts | February 07, 2019
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for the Valiant Navion thoracic stent...
Endologix Ends Unrestricted Sales and Use of Nellix System
News | Stent Grafts | January 07, 2019
January 7, 2019 — Endologix Inc.
Endologix Reports Positive One-Year Results From the Ovation LUCY Study
News | Stent Grafts | July 16, 2018
Endologix Inc. announced one-year results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for...
FDA Committee Votes in Favor of Incraft AAA Stent Graft System
News | Stent Grafts | June 13, 2018
Cardinal Health announced that its Incraft Abdominal Aortic Aneurysm (AAA) Stent Graft System has received a favorable...
First Patient Enrolled in Gore Excluder Investigational Study
News | Stent Grafts | January 08, 2018
January 8, 2018 — W. L. Gore & Associates Inc.
Overlay Init